HQ Azithromycin

[hehateme82]

These drugs work as a preventative and in the early stages against Covid-19.

I am currently taking something similar to knock out several vector borne disease (bartonella, borellia, babesia to name a few). I am on disulfiram and azithro. Disulfiram also kills Covid-19 in vitro and is currently being explored to combat HIV, Cancer, Alzheimer's, etc. I could literally roll around in the virus and not get it. There is no excuse for HCQ and Azithro to not be at the hands of every medical professional. There are very few side effects of HDQ and Azithro and the benefit is there.

The data is there. This has been nothing short of one of the largest scandal in modern day medicine. All the negative studies can be easily dissected to show bias. Fauci strikes again.

If anyone wants to prove me otherwise, by all means...

 

[hehateme82]

There are over 200 FDA approved drugs that kill Covid in vitro. HCQ and disulfiram being top of the list. Obviously not every drug that kills in vitro translates to in human. But here's the disturbing part, how many studies did the CDC, NIH, NIAID, Fauci fund or organize to take to the next phase?

 

[hehateme82]

NIH was funding three studies then cancelled two after the fake Lancet New England Journal falsely claimed HCQ caused severe heart issues. Study was retracted in early June but the damage was done as the studies were cancelled and Fauci was already committed to his baby... remdesivir. The third study was to see if HCQ was effective as a preventative for front line works and we are waiting for an update. Been pretty quiet though.

 

[hehateme82]

Fauci calls Remdesivir the new standard of care of Covid. Huh? it reduces hospilitaztion from 15 days to 11? That's the new standard of care. We aren't going to see if any of the other 200 FDA approved drugs that kill covid in vitro could be repurposed for Covid and beat that? Oh and Remdesivir failed against ebola as it was designed and is not FDA approved. It has more side effects than HCQ.

 

[hehateme82]

Top Yale and Harvard Doctors

Medical Studies Support MDs Prescribing Hydroxychloroquine for Early Stage COVID-19 and for Prophylaxis

by
[h=4]Vladimir Zelenko, M.D.[/h] [h=4]Harvey A. Risch, M.D., PH.D.[/h] [h=4]George C. Fareed, M.D.[/h] JRC Publishing LLC, New Jersey has published an important book on treatment of COVID-19 virus. The book is based on medical research and treatment conducted by Dr. Roland Derwand, Prof. Martin Scholz and Dr. Zelenko.

https://internetprotocol.co/covid-19/2020/07/21/yale-harvard-professors-support-zelenkos-protocol/

 

[hehateme82]

The weekly ratio of COVID patients healed to dead keeps reaching new highs in Brazil as more and more municipalities turn to COVID kits with hydroxychloroquine+azithromycin (+/-ivermectin) for early at home treatment. Very strong observational data in favor of HCQ now.

 

[StevieRay]

Fauci calls Remdesivir the new standard of care of Covid. Huh? it reduces hospilitaztion from 15 days to 11? That's the new standard of care. We aren't going to see if any of the other 200 FDA approved drugs that kill covid in vitro could be repurposed for Covid and beat that? Oh and Remdesivir failed against ebola as it was designed and is not FDA approved. It has more side effects than HCQ.

Fauci the fake?

 

[hehateme82]

Fauci the fake?

It's insane that he was able to get away with HCQ ban. 200 already FDA approved drugs that kill covid in vitro and fauci doesn't think it's a good idea to take any of them to the next phase? Nah, let's wait around few months while people die and see if we can get the at vaccine. Then he completely torpedoes HCQ and Azithro in the meantime because of bad study. HCQ has been around forever and is still the first protocol used for Americans who are traveling to malaria ridden countries. But over night it is causing people to have sever heart problems? What in the actually fuck. The CDC has a frequently asked HCQ page. I shit you not:


https://www.cdc.gov/malaria/resourc..._crh1lro-BHlgFiqXT7sOP30lNVtTLvWCxZT5dcbB4MuM


This shit is beyond fucked up.

 

[StevieRay]

Hydroxychloroquine could save up to 100,000 lives if used for COVID-19: Yale epidemiology professor

 

[timbo41]

Hydroxychloroquine with zinc will turn out to be the closest thing to a vaccine we will ever see. This acknowledgement will occur after the election.

 

[halekulani]

https://www.jwatch.org/na51549/2020/05/13/lack-efficacy-hydroxychloroquine-or-azithromycin-covid-19
Two retrospective studies of COVID-19 patients in New York found no impact of hydroxychloroquine with or without azithromycin on risk of intubation or death.

Interest in hydroxychloroquine and chloroquine with or without azithromycin in treating patients with COVID-19 has been high since early reports suggested that using these drugs improved outcomes. This interest intensified with the FDA decision to issue an emergency-use authorization to allow their use for this indication. To help assess the actual efficacy of hydroxychloroquine with or without azithromycin, two groups of researchers undertook reviews of patients with COVID-19 admitted to New York hospitals between March and April 2020, when these agents were being used commonly to treat the infection. In the study by Geleris and colleagues, the primary analysis compared the risk for intubation or death in hydroxychloroquine recipients and nonrecipients, with an adjustment for predictors of respiratory failure and weighting according to propensity score for the probability of hydroxychloroquine use. For Rosenberg and colleagues, hospital mortality was the primary outcome.
Of 1376 patients assessed by Geleris, 811 (59%) received hydroxychloroquine, 86% of these starting within 48 hours of presentation. The patients who received hydroxychloroquine were more severely ill than those who did not according to multiple clinical and laboratory parameters. In an unadjusted analysis, patients who received hydroxychloroquine were significantly more likely to be intubated or die than those who did not (hazard ratio, 2.37; 95% confidence interval, 1.84–3.02). An adjusted analysis including the 811 hydroxychloroquine recipients and 274 nonrecipients with COVID-19 showed no significant difference in the composite endpoint of intubation or death (hazard ratio, 1.04; 95% CI, 0.82–1.32). Numerous sensitivity analyses had similar findings.
Rosenberg assessed 1438 patients hospitalized with COVID-19 who received hydroxychloroquine alone (271 patients) or with azithromycin (735 patients), azithromycin alone (211 patients), or neither drug (221 patients). Overall in-hospital mortality was 20.3%. There was no significant difference in mortality across the groups. Cardiac arrest was significant more likely in patients receiving hydroxychloroquine with azithromycin.

https://www.nejm.org/doi/full/10.1056/NEJMoa2012410
In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed. (Funded by the National Institutes of Health.)

https://www.nejm.org/doi/full/10.1056/NEJMoa2016638
CONCLUSIONS

After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668. opens in new tab.)

https://jamanetwork.com/journals/jama/fullarticle/2766117
Conclusions and RelevanceAmong patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. However, the interpretation of these findings may be limited by the observational design.

----
tl;dr
trials with both early therapy and after high risk exposure have not shown benefit
the end.

 

[brendanjack]

The pricing of remdesivir is off the charts over3k a pill and Gilead pharmaceuticals said average person would need 6 doses yet that was the price they agreed on with private health and they offered it to other governments for 3-400 a pill go figure .

 

[brendanjack]

Hydroxychloroquine with zinc will turn out to be the closest thing to a vaccine we will ever see. This acknowledgement will occur after the election.

You ain’t kidding and it’s a fraction of the cost if trump gets re-elected they won’t give him credit for shit.

 

[PatsFanatic]

https://www.jwatch.org/na51549/2020/05/13/lack-efficacy-hydroxychloroquine-or-azithromycin-covid-19
Two retrospective studies of COVID-19 patients in New York found no impact of hydroxychloroquine with or without azithromycin on risk of intubation or death.

Interest in hydroxychloroquine and chloroquine with or without azithromycin in treating patients with COVID-19 has been high since early reports suggested that using these drugs improved outcomes. This interest intensified with the FDA decision to issue an emergency-use authorization to allow their use for this indication. To help assess the actual efficacy of hydroxychloroquine with or without azithromycin, two groups of researchers undertook reviews of patients with COVID-19 admitted to New York hospitals between March and April 2020, when these agents were being used commonly to treat the infection. In the study by Geleris and colleagues, the primary analysis compared the risk for intubation or death in hydroxychloroquine recipients and nonrecipients, with an adjustment for predictors of respiratory failure and weighting according to propensity score for the probability of hydroxychloroquine use. For Rosenberg and colleagues, hospital mortality was the primary outcome.
Of 1376 patients assessed by Geleris, 811 (59%) received hydroxychloroquine, 86% of these starting within 48 hours of presentation. The patients who received hydroxychloroquine were more severely ill than those who did not according to multiple clinical and laboratory parameters. In an unadjusted analysis, patients who received hydroxychloroquine were significantly more likely to be intubated or die than those who did not (hazard ratio, 2.37; 95% confidence interval, 1.84–3.02). An adjusted analysis including the 811 hydroxychloroquine recipients and 274 nonrecipients with COVID-19 showed no significant difference in the composite endpoint of intubation or death (hazard ratio, 1.04; 95% CI, 0.82–1.32). Numerous sensitivity analyses had similar findings.
Rosenberg assessed 1438 patients hospitalized with COVID-19 who received hydroxychloroquine alone (271 patients) or with azithromycin (735 patients), azithromycin alone (211 patients), or neither drug (221 patients). Overall in-hospital mortality was 20.3%. There was no significant difference in mortality across the groups. Cardiac arrest was significant more likely in patients receiving hydroxychloroquine with azithromycin.

https://www.nejm.org/doi/full/10.1056/NEJMoa2012410
In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed. (Funded by the National Institutes of Health.)

https://www.nejm.org/doi/full/10.1056/NEJMoa2016638
CONCLUSIONS

After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668. opens in new tab.)

https://jamanetwork.com/journals/jama/fullarticle/2766117
Conclusions and RelevanceAmong patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. However, the interpretation of these findings may be limited by the observational design.

----
tl;dr
trials with both early therapy and after high risk exposure have not shown benefit
the end.

2.5 month old article that ends with....

[h=2]COMMENT[/h]Both studies are observational and subject to many limitations that a well-conducted randomized, controlled trial would not have. None of the findings supports the use of hydroxychloroquine with or without azithromycin for COVID-19. Given the potential adverse cardiac effects that could arise, we personally will reserve its use pending the results of controlled clinical trials.

 

[halekulani]

2.5 month old article that ends with....

COMMENT

Both studies are observational and subject to many limitations that a well-conducted randomized, controlled trial would not have. None of the findings supports the use of hydroxychloroquine with or without azithromycin for COVID-19. Given the potential adverse cardiac effects that could arise, we personally will reserve its use pending the results of controlled clinical trials.

again, trials so far have not shown benefit

trials are pending, yes, but to date, there is no data to support the claim the OP is making. to prove it works, there has to be 1. evidence that is 2. reproducible.

so even if the next RCT publication comes out saying they see a benefit, it has to be reproduced and supported by studies using the same treatment algorithm and addressing weaknesses in the original experimental design.

 

[PatsFanatic]

again, trials so far have not shown benefit

trials are pending, yes, but to date, there is no data to support the claim the OP is making. to prove it works, there has to be 1. evidence that is 2. reproducible.

so even if the next RCT publication comes out saying they see a benefit, it has to be reproduced and supported by studies using the same treatment algorithm and addressing weaknesses in the original experimental design.

Looks like your resource gave a bunch of really sick patients Hydro that obviously didn't work at that stage. OP talking about as a preventative/early sign treatment which has had a lot of success from around the world. I've seen positive articles elsewhere as well.

 

[halekulani]

Looks like your resource gave a bunch of really sick patients Hydro that obviously didn't work at that stage. OP talking about as a preventative/early sign treatment which has had a lot of success from around the world. I've seen positive articles elsewhere as well.

....

https://www.nejm.org/doi/full/10.1056/NEJMoa2016638
"We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. We enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days after exposure, we randomly assigned participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days). The primary outcome was the incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days.

Results
We enrolled 821 asymptomatic participants. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact. The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%])"

CONCLUSIONS

After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668. opens in new tab.)

 

[hehateme82]

=

....

https://www.nejm.org/doi/full/10.1056/NEJMoa2016638
"We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. We enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days after exposure, we randomly assigned participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days). The primary outcome was the incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days.

Results
We enrolled 821 asymptomatic participants. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact. The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%])"

CONCLUSIONS

After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668. opens in new tab.)

I was hoping someone would bring up the U of M Study by Dr. Boulware. Don't have time right now, but let's just say there are major issues. Oh, he has close ties to Gilead for starters but that won't matter after the flaws are revealed.

 

[Albatross]

Fauci calls Remdesivir the new standard of care of Covid. Huh? it reduces hospilitaztion from 15 days to 11? That's the new standard of care. We aren't going to see if any of the other 200 FDA approved drugs that kill covid in vitro could be repurposed for Covid and beat that? Oh and Remdesivir failed against ebola as it was designed and is not FDA approved. It has more side effects than HCQ.

Does he have any stake in that drug? If so people need to open their eyes.......these guys are damn snakes

 

[Willie99]

2.5 month old article that ends with....

COMMENT

Both studies are observational and subject to many limitations that a well-conducted randomized, controlled trial would not have. None of the findings supports the use of hydroxychloroquine with or without azithromycin for COVID-19. Given the potential adverse cardiac effects that could arise, we personally will reserve its use pending the results of controlled clinical trials.

Saw a doctor talking about the use of hydroxychloroquine, he said he's been administering to Lupus patients for 20 or 30 years, prescribed it to thousands of patients, not one ever had a heart attack

FWIW

the side effects may be just a tad bit overstated, it's a lawyer thing